Given the unique tumor vascular system and the ability of platelets to adhere to circulating tumor cells—especially through surface receptors such as GP IIb/IIIa—innovative targeting strategies have been designed to leverage platelet accumulation in tumors. The gene discussed is ITGA2B; the disease is neoplasm.